ReviewNeurochemistry international2014
Moving beyond energy homeostasis: new roles for glucagon-like peptide-1 in food and drug reward.
Review in Neurochemistry international, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 30 citations in OpenAlex.
- GLP-1 and Dual GIP/GLP-1 Receptor Agonists in Pediatric Obesity: From Neuroendocrine Mechanisms to Clinical Application.International journal of molecular sciences · 2026Review
- GLP-1-targeted therapies for alcohol and other substance use disorders: a new era on the horizon?The Journal of clinical investigation · 2026Article
- Review
- Unravelling obesity: from leptin to glucagon-like peptide-1 receptor agonists.Journal of applied genetics · 2026Review
- Crosstalk between alcohol use disorder and obesity: two sides of the same coin?Molecular psychiatry · 2025Review
- Effects of glucagon-like peptide-1 receptor agonists on alcohol consumption: a systematic review and meta-analysis.EClinicalMedicine · 2025Article
- Article
- Glucagon-like peptide-1 receptor agonists, but not dipeptidyl peptidase-4 inhibitors, reduce alcohol intake.The Journal of clinical investigation · 2025Article
- Clinical Factors Associated with Body-weight Reduction Induced by Semaglutide 1.0 mg Weekly in Patients with Type 2 Diabetes Mellitus.JMA journal · 2025Article
- Article
- Molecular mechanisms of semaglutide and liraglutide as a therapeutic option for obesity.Frontiers in nutrition · 2024Review
- The glucagon-like peptide-1 system is modulated by acute and chronic alcohol exposure: Findings from human laboratory experiments and a post-mortem brain study.Addiction biology · 2022Article
- The role of glucagon-like peptide 1 (GLP-1) in addictive disorders.British journal of pharmacology · 2022Review
- Possible Mechanisms Underlying the Effects of Glucagon-Like Peptide-1 Receptor Agonist on Cocaine Use Disorder.Frontiers in pharmacology · 2022Review
- Effects of Liraglutide and Behavioral Weight Loss on Food Cravings, Eating Behaviors, and Eating Disorder Psychopathology.Obesity (Silver Spring, Md.) · 2019Article
- Tobacco Smoking, Eating Behaviors, and Body Weight: A Review.Current addiction reports · 2019Article
- Vagal Interoceptive Modulation of Motivated Behavior.Physiology (Bethesda, Md.) · 2018Review
- The dopamine motive system: implications for drug and food addiction.Nature reviews. Neuroscience · 2017Review
- Glucagon-like peptide 1 receptor activation regulates cocaine actions and dopamine homeostasis in the lateral septum by decreasing arachidonic acid levels.Translational psychiatry · 2016Article
- How Does the Brain Implement Adaptive Decision Making to Eat?The Journal of neuroscience : the official journal of the Society for Neuroscience · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Glucagon-like peptide-1 (GLP-1), a hormone and neuropeptide, is known to regulate energy homeostasis in part through an established central role in controlling food intake. Historically this central role has largely been attributed to GLP-1 receptor signaling in the brainstem and hypothalamus. However, emerging data indicate that GLP-1 also contributes to non-homeostatic regulation of food reward and motivated behaviors in brain reward centers, including the ventral tegmental area and nucleus accumbens. The hypothesis that GLP-1 signaling modulates reward circuitry has provided the impetus for studies demonstrating that GLP-1 attenuates reward for psychostimulants and alcohol. Here, we examine current evidence for GLP-1-mediated regulation of food and drug reward and use these findings to hypothesize mechanisms of action within brain reward centers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.